1.	Skin Cancer Prevention Phase: Phase IV Type: Prevention Status: Active Age: No age specified Sponsor: Other Protocol IDs: 562, NCT00847912
2.	Selenium in Treating Patients With Adenomatous Colorectal Polyps Phase: Phase III Type: Prevention Status: Active Age: 40 to 80 Sponsor: NCI Protocol IDs: UARIZ-00-0430-01, 00-0430-01, UARIZ-HSC-00142, NCT00078897
3.	Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer Phase: Phase III Type: Prevention Status: Active Age: 35 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CAN-NCIC-MAP3, PFIZER-EXEAPO-0028-150, ExCel, NCT00083174, MAP3
4.	Erlotinib Prevention of Oral Cancer (EPOC) Phase: Phase III Type: Prevention Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 2003-0824, EPOC, NCT00402779
5.	Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women Phase: Phase III Type: Prevention Status: Active Age: 16 to 26 Sponsor: Pharmaceutical / Industry Protocol IDs: 2007_538, NCT00543543
6.	Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US Phase: Phase III Type: Prevention Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 111955, NCT00799825
7.	Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women Phase: Phase III Type: Prevention Status: Active Age: 30 to 75 Sponsor: Other Protocol IDs: GD-10-08, NCT00808522
8.	A Study of V503 in Preadolescents and Adolescents Phase: Phase III Type: Prevention Status: Active Age: 9 to 26 Sponsor: Pharmaceutical / Industry Protocol IDs: 2009_611, NCT00943722
9.	A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds Phase: Phase III Type: Prevention Status: Active Age: 11 to 15 Sponsor: Pharmaceutical / Industry Protocol IDs: 2009_670, NCT00988884
10.	Evaluation of 20% Betulinic Acid Ointment for Treatment of Dysplastic Nevi (Moderate to Severe Dysplasia) Phase: Phase II, Phase I Type: Prevention Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2003-0811, NCT00346502
11.	Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2 Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 0405-2006, NCT00400374
12.	Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor Phase: Phase II, Phase I Type: Prevention Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 0596-2004, NCT00314262
13.	Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease Phase: Phase II Type: Prevention Status: Active Age: 21 to 48 Sponsor: NCI Protocol IDs: CHNMC-IRB-02164, NCT00080756
14.	Exemestane in Treating Postmenopausal Women at High Risk for Invasive Breast Cancer Phase: Phase II Type: Prevention Status: Active Age: Postmenopausal Sponsor: NCI Protocol IDs: GUMC-2007-313, NCI-04-C-0044, NCT00085072, GUMC-2007-313, GT 07-313, 2007-313
15.	Curcumin for the Chemoprevention of Colorectal Cancer Phase: Phase II Type: Prevention Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 802193, NCT00118989
16.	Soy Protein and Breast Cancer Risk Reduction Phase: Phase II Type: Prevention Status: Active Age: 30 to 40 Sponsor: Other Protocol IDs: 02-422, Army's HSRRB log no. A-10926, UTMB GCRC 533, DAMD17-01-1-0417, NIH NCRR GCRC M01 RR00073, NCT00204477
17.	Soy Isoflavones and Breast Cancer Risk Reduction Phase: Phase II Type: Prevention Status: Active Age: 30 to 42 Sponsor: NCI, Other Protocol IDs: 03-260, UTMB GCRC #635, NIH R01-CA95545, NIH NCRR GCRC M01 RR00073, NCT00204490
18.	Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs) Phase: Phase II Type: Prevention Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 0305-20, NCT00198081
19.	Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia Phase: Phase II Type: Prevention Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UARIZ-UAZ03-1-02, UARIZ-HSC-0540, UAZ03-1-02, NCT00303823
20.	Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries Phase: Phase II Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Prevention Status: Active Age: Not specified Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: GOG-0215, 0215, NOVARTIS-GOG-0215, NCI-06-C-0204, NCI-P6966, NCT00305695
21.	Phase II Trial - Breast Cancer Chemoprevention by Lovastatin Phase: Phase II Type: Biomarker/Laboratory analysis, Diagnostic, Prevention Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: BRSNSTU0010, NCT00285857
22.	Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UCIRVINE-UCI-98-34, UCIRVINE-UCI-1998-521, NCT00330382, U01-CA-72294
23.	Simvastatin in Preventing a New Breast Cancer in Women Who Are at High Risk for a New Breast Cancer After Undergoing Surgery for Ductal Carcinoma in Situ or Stage I, Stage II, or Stage III Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: JHOC-J0485, J0485, JHOC-SKCCC-J0485, JHOC-04100404, NCT00334542
24.	Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 40 to 79 Sponsor: NCI Protocol IDs: MAYO-03-1-02, MAY03-1-02, NCT00368927
25.	Enzastaurin in Preventing Non-Small Cell Lung Cancer in Former Smokers Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 45 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MCC-14787, H6Q-MC-S009, MCC-104545, LILLY-H6Q-MC-S009A, U01-CA-101222, NCT00387816